Last reviewed · How we verify
Eviplera®
Eviplera is a fixed-dose combination of three antiretroviral drugs that work together to suppress HIV replication by inhibiting reverse transcriptase and integrase enzymes.
Eviplera is a fixed-dose combination of three antiretroviral drugs that work together to suppress HIV replication by inhibiting reverse transcriptase and integrase enzymes. Used for HIV-1 infection in treatment-naïve adults with viral load ≤100,000 copies/mL.
At a glance
| Generic name | Eviplera® |
|---|---|
| Also known as | emtricitabine/rilpivirine/tenofovir, Rilpivirine, tenofovir, emtricitabine |
| Sponsor | St Stephens Aids Trust |
| Drug class | Antiretroviral combination therapy (NNRTI + NRTI + NtRTI) |
| Target | HIV reverse transcriptase, HIV integrase |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease / Virology |
| Phase | FDA-approved |
Mechanism of action
Eviplera combines rilpivirine (a non-nucleoside reverse transcriptase inhibitor), emtricitabine (a nucleoside reverse transcriptase inhibitor), and tenofovir disoproxil fumarate (a nucleotide reverse transcriptase inhibitor). Together, these agents target different steps of HIV replication, preventing the virus from converting its RNA genome into DNA and integrating into host cells, thereby reducing viral load and slowing disease progression.
Approved indications
- HIV-1 infection in treatment-naïve adults with viral load ≤100,000 copies/mL
Common side effects
- Rash
- Diarrhea
- Nausea
- Headache
- Abnormal liver function tests
- Renal impairment
Key clinical trials
- Switch Study to Evaluate the Safety and Efficacy of Emtricitabine/Rilpivirine/Tenofovir Alafenamide (FTC/RPV/TAF) Fixed Dose Combination (FDC) in HIV-1 Positive Adults Who Are Virologically Suppressed on Emtricitabine/Rilpivirine/Tenofovir Disoproxil Fumarate (FTC/RPV/TDF) (PHASE3)
- SSAT058: Atripla to Eviplera Switch in Patients Without Central Nervous System Symptoms (PHASE4)
- Evolution of Plasma Lipid Profile in Patients With HIV1 Who Change Atripla to Eviplera Compared to Continue With Atripla (PHASE4)
- Study to Evaluate Switching From Regimens Consisting of a Ritonavir-boosted Protease Inhibitor (PI) and Two Nucleoside Reverse Transcriptase Inhibitors (NRTIs) to a Fixed-dose Tablet Containing Emtricitabine/Rilpivirine/Tenofovir DF (PHASE3)
- Hepatic Safety of Eviplera® in HIV/Hepatitis C (HCV)-Coinfected Patients Without HCV Treatment in the "The HEPAVIR HEPATIC SAFETY Cohort."
- Study to Evaluate the Safety and Efficacy of a Single Tablet Regimen of Emtricitabine/Rilpivirine/Tenofovir Disoproxil Fumarate Compared With a Single Tablet Regimen of Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate in HIV-1 Infected, Antiretroviral Treatment-Naive Adults (PHASE3)
- Pharmacokinetics of Tenofovir and Tenofovir-diphosphate, Emtricitabine and Emtricitabine-triphosphate, and Rilpivirine Once Daily Over 14 Days Following Drug Intake Cessation in Healthy Volunteers (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |